Your browser doesn't support javascript.
loading
Degradation of specific glycosaminoglycans improves transfection efficiency and vector production in transient lentiviral vector manufacturing processes.
Williams-Fegredo, Thomas; Davies, Lee; Knevelman, Carol; Mitrophanous, Kyriacos; Miskin, James; Rafiq, Qasim A.
Afiliación
  • Williams-Fegredo T; Oxford Biomedica (UK) Limited, Oxford, United Kingdom.
  • Davies L; Department of Biochemical Engineering, Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom.
  • Knevelman C; Oxford Biomedica (UK) Limited, Oxford, United Kingdom.
  • Mitrophanous K; Oxford Biomedica (UK) Limited, Oxford, United Kingdom.
  • Miskin J; Oxford Biomedica (UK) Limited, Oxford, United Kingdom.
  • Rafiq QA; Oxford Biomedica (UK) Limited, Oxford, United Kingdom.
Front Bioeng Biotechnol ; 12: 1409203, 2024.
Article en En | MEDLINE | ID: mdl-38994127
ABSTRACT
Both cell surface and soluble extracellular glycosaminoglycans have been shown to interfere with the exogenous nucleic acid delivery efficiency of non-viral gene delivery, including lipoplex and polyplex-mediated transfection. Most gene therapy viral vectors used commercially and in clinical trials are currently manufactured using transient transfection-based bioprocesses. The growing demand for viral vector products, coupled with a global shortage in production capability, requires improved transfection technologies and processes to maximise process efficiency and productivity. Soluble extracellular glycosaminoglycans were found to accumulate in the conditioned cell culture medium of suspension adapted HEK293T cell cultures, compromising transfection performance and lentiviral vector production. The enzymatic degradation of specific, chondroitin sulphate-based, glycosaminoglycans with chondroitinase ABC was found to significantly enhance transfection performance. Additionally, we report significant improvements in functional lentiviral vector titre when cultivating cells at higher cell densities than those utilised in a control lentiviral vector bioprocess; an improvement that was further enhanced when cultures were supplemented with chondroitinase ABC prior to transfection. A 71.2% increase in functional lentiviral vector titre was calculated when doubling the cell density prior to transfection compared to the existing process and treatment of the high-density cell cultures with 0.1 U/mL chondroitinase ABC resulted in a further 18.6% increase in titre, presenting a method that can effectively enhance transfection performance.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Bioeng Biotechnol Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Bioeng Biotechnol Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Suiza